9 recruiting, 6 not yet recruiting, 3 completed, 3 unknown. 24 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 24 | Recruiting 9, Not yet recruiting 6, Completed 3, Unknown 3, Enrolling by invitation 2, Withdrawn 1 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Safety and Efficacy of ONT01 in Lupus ONT01 is a small molecule CD11b modulator. - Lupus Nephritis (LN), Lupus Nephritis - WHO Class III | Early Phase 1 | Recruiting | Hospital for Special Surgery, New York | 61 | 2026-09-04 | 2025-11-20 |
| RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases RD06-05 CART Cell Infusion - Autoimmune Diseases, SLE - Systemic Lupus Erythematosus | Early Phase 1 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 30 | 2026-07-01 | 2026-06-29 |
| CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease QT-219CX - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-05-08 | 2026-05-14 |
| A Study of YKST02 in Participants With Primary IgA Nephropathy YKST02 - Primary IgA Nephropathy | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-05-06 | 2026-05-12 |
| Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy CD19 CAR-γδ T cell - Membranous Nephropathy, Lupus Nephritis (LN) | Early Phase 1 | Not yet recruiting | Air Force Military Medical University, China | 15 | 2026-05-01 | 2026-04-16 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing - Refractory Idiopathic Membranous Nephropathy | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | 18 | 2026-02-28 | 2026-02-20 |
| An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy anti-CD19/BCMA CAR NK cells - IgA Nephropathy (IgAN) | Early Phase 1 | Withdrawn | Jieyang People's Hospital | 2025-07-30 | 2025-07-04 | |
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. RD06-05 CART Cell Injection - SLE, LN | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 96 | 2025-07-24 | 2026-08-03 |
| A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy Biological: cizutamig - Immunoglobulin A Nephropathy (IgAN) | Early Phase 1 | Enrolling by invitation | Peking University First Hospital | 15 | 2025-07-16 | 2025-08-22 |
| The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome. SCFA → Placebo (Sequence SP) and Placebo → SCFA (Sequence PS) - Primary IgA Nephropathy | Early Phase 1 | Enrolling by invitation | University Hospital, Martin | 120 | 2025-03-01 | 2026-08-06 |
| CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection - Lupus Nephritis | Early Phase 1 | Recruiting | He Huang | 9 | 2025-01-31 | 2025-01-21 |
| Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease anti-CD19/BCMA CAR NK cells (KN5601) - Autoimmune Diseases, Systemic Lupus Erthematosus | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 36 | 2025-01-30 | 2025-12-01 |
| A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus LCAR-AIO T cells - Systemic Lupus Erythematosus (SLE) | Early Phase 1 | Completed | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 | 2025-01-08 | 2026-10-14 |
| IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients IM19 chimeric antigen receptor T cell injection - IgA Nephropathy, Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-12-13 | 2024-11-26 |
| Universal CAR-T Cell Therapy for Refractory Lupus Nephritis BCMA CART + CD19 CART - Lupus Nephritis | Early Phase 1 | Unknown | Bioray Laboratories | 10 | 2024-11-25 | 2024-11-08 |
| Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis Umbilical cord mesenchymal stem cells, Normal saline - Lupus Nephritis | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 96 | 2024-10-01 | 2024-07-03 |
| Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease PRG-1801 - Lupus Nephritis, IgG4-related Disease | Early Phase 1 | Recruiting | Tongji Hospital | 30 | 2024-07-01 | 2024-07-11 |
| Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease PRG-2311 - Lupus Nephritis, IgG4-related Disease | Early Phase 1 | Recruiting | Tongji Hospital | 30 | 2024-07-01 | 2024-07-11 |
Showing 20 of 24. Sign in to see all of them.
Glomerulonephritis, IGA (12) · Lupus Nephritis (10) · Autoimmune Diseases (5) · Glomerulonephritis, Membranous (5) · Lupus Erythematosus, Systemic (4) · Nephrotic Syndrome (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Immunoglobulin G4-Related Disease (2) · Scleroderma, Systemic (2) · Anemia, Hemolytic, Autoimmune (1) · Anti-Glomerular Basement Membrane Disease (1) · Glomerulosclerosis, Focal Segmental (1) · Hypertension, Pulmonary (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Recurrence (1)
Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Kidney Diseases (24) · Male Urogenital Diseases (24) · Nephritis (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Immune System Diseases (23) · Autoimmune Diseases (18) · Skin and Connective Tissue Diseases (15) · Connective Tissue Diseases (13) · Lupus Erythematosus, Systemic (7) · Cardiovascular Diseases (4) · Nephrosis (4)
Rituximab (2) · Plasmapheresis (1) · Saline Solution (1)
The Children's Hospital of Zhejiang University School of Medicine (4) · Tongji Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Air Force Military Medical University, China (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Bioray Laboratories (1) · Chinese PLA General Hospital (1) · Grit Biotechnology (1) · He Huang (1) · Hospital for Special Surgery, New York (1) · Jieyang People's Hospital (1) · Mayo Clinic (1) · Nanjing Bioheng Biotech Co., Ltd. (1) · Peking Union Medical College Hospital (1) · Peking University First Hospital (1)
China (17) · United States (3) · Slovakia (1)
Daobin Zhou, Dr (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · He Huang, MD (1) · He Huang, PhD (1) · Jianhua Mao (1) · Lingli Dong (1) · Lingli Dong, MD (1) · Michelle Rheault, MD (1) · Xiangmei Chen (1) · Xiaofeng Zeng, Dr (1)